vs
Axsome Therapeutics, Inc.（AXSM）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是Axsome Therapeutics, Inc.的1.0倍（$200.5M vs $196.0M），ROGERS CORP净利率更高（2.2% vs -14.6%，领先16.8%），Axsome Therapeutics, Inc.同比增速更快（65.0% vs 5.2%），ROGERS CORP自由现金流更多（$1.1M vs $-18.7M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（61.7% vs -3.3%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
AXSM vs ROG — 直观对比
营收规模更大
ROG
是对方的1.0倍
$196.0M
营收增速更快
AXSM
高出59.8%
5.2%
净利率更高
ROG
高出16.8%
-14.6%
自由现金流更多
ROG
多$19.8M
$-18.7M
两年增速更快
AXSM
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $196.0M | $200.5M |
| 净利润 | $-28.6M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | -13.8% | — |
| 净利率 | -14.6% | 2.2% |
| 营收同比 | 65.0% | 5.2% |
| 净利润同比 | 61.9% | 421.4% |
| 每股收益（稀释后） | $-0.55 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $196.0M | $201.5M | ||
| Q3 25 | $171.0M | $216.0M | ||
| Q2 25 | $150.0M | $202.8M | ||
| Q1 25 | $121.5M | $190.5M | ||
| Q4 24 | $118.8M | $192.2M | ||
| Q3 24 | $104.8M | $210.3M | ||
| Q2 24 | $87.2M | $214.2M |
净利润AXSMROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-28.6M | $4.6M | ||
| Q3 25 | $-47.2M | $8.6M | ||
| Q2 25 | $-48.0M | $-73.6M | ||
| Q1 25 | $-59.4M | $-1.4M | ||
| Q4 24 | $-74.9M | $-500.0K | ||
| Q3 24 | $-64.6M | $10.7M | ||
| Q2 24 | $-79.3M | $8.1M |
毛利率AXSMROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率AXSMROG
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 3.5% | ||
| Q3 25 | -27.0% | 7.3% | ||
| Q2 25 | -24.5% | -33.3% | ||
| Q1 25 | -46.9% | -0.2% | ||
| Q4 24 | -61.1% | -6.6% | ||
| Q3 24 | -59.8% | 6.9% | ||
| Q2 24 | -89.5% | 5.3% |
净利率AXSMROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | -14.6% | 2.3% | ||
| Q3 25 | -27.6% | 4.0% | ||
| Q2 25 | -32.0% | -36.3% | ||
| Q1 25 | -48.9% | -0.7% | ||
| Q4 24 | -63.1% | -0.3% | ||
| Q3 24 | -61.7% | 5.1% | ||
| Q2 24 | -91.0% | 3.8% |
每股收益（稀释后）AXSMROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.55 | $0.20 | ||
| Q3 25 | $-0.94 | $0.48 | ||
| Q2 25 | $-0.97 | $-4.00 | ||
| Q1 25 | $-1.22 | $-0.08 | ||
| Q4 24 | $-1.54 | $-0.04 | ||
| Q3 24 | $-1.34 | $0.58 | ||
| Q2 24 | $-1.67 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $322.9M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $88.3M | $1.2B |
| 总资产 | $689.8M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $322.9M | $197.0M | ||
| Q3 25 | $325.3M | $167.8M | ||
| Q2 25 | $303.0M | $157.2M | ||
| Q1 25 | $300.9M | $175.6M | ||
| Q4 24 | $315.4M | $159.8M | ||
| Q3 24 | $327.3M | $146.4M | ||
| Q2 24 | $315.7M | $119.9M |
股东权益AXSMROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.2B | ||
| Q1 25 | $53.2M | $1.3B | ||
| Q4 24 | $57.0M | $1.3B | ||
| Q3 24 | $92.9M | $1.3B | ||
| Q2 24 | $102.9M | $1.3B |
总资产AXSMROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $689.8M | $1.4B | ||
| Q3 25 | $669.3M | $1.4B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.5B | ||
| Q4 24 | $568.5M | $1.5B | ||
| Q3 24 | $561.5M | $1.5B | ||
| Q2 24 | $548.2M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.7M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $-18.7M | $1.1M |
| 自由现金流率自由现金流/营收 | -9.6% | 0.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | $-93.9M | $70.1M |
8季度趋势，按日历期对齐
经营现金流AXSMROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-18.7M | $46.9M | ||
| Q3 25 | $1.0M | $28.9M | ||
| Q2 25 | $-32.4M | $13.7M | ||
| Q1 25 | $-43.4M | $11.7M | ||
| Q4 24 | $-26.2M | $33.7M | ||
| Q3 24 | $-18.6M | $42.4M | ||
| Q2 24 | $-30.1M | $22.9M |
自由现金流AXSMROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-18.7M | $42.2M | ||
| Q3 25 | $988.0K | $21.2M | ||
| Q2 25 | $-32.4M | $5.6M | ||
| Q1 25 | $-43.7M | $2.1M | ||
| Q4 24 | $-26.2M | $18.3M | ||
| Q3 24 | $-18.7M | $25.2M | ||
| Q2 24 | $-30.2M | $8.8M |
自由现金流率AXSMROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | -9.6% | 20.9% | ||
| Q3 25 | 0.6% | 9.8% | ||
| Q2 25 | -21.6% | 2.8% | ||
| Q1 25 | -36.0% | 1.1% | ||
| Q4 24 | -22.1% | 9.5% | ||
| Q3 24 | -17.9% | 12.0% | ||
| Q2 24 | -34.6% | 4.1% |
资本支出强度AXSMROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.3% | 5.0% | ||
| Q4 24 | 0.0% | 8.0% | ||
| Q3 24 | 0.1% | 8.2% | ||
| Q2 24 | 0.1% | 6.6% |
现金转化率AXSMROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
